Please login to the form below

Not currently logged in
Email:
Password:

Heptares Pharma

This page shows the latest Heptares Pharma news and features for those working in and with pharma, biotech and healthcare.

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

Tox trouble stalls Sosei/Allergan Alzheimer’s drug

The drug is one of the lead candidate from a $3.35bn licensing deal Allergan agreed with Sosei’s Heptares Pharma subsidiary two years ago, covering global rights to a portfolio

Latest news

  • Teva buys into Heptares oral CGRP programme for migraine Teva buys into Heptares oral CGRP programme for migraine

    Signs$410m alliance for early-stage candidates in potentially-lucrative drug class. Teva will co-develop Heptares Pharma's portfolio of migraine therapies in a new alliance valued at up to $410m. ... The agreement - which includes a $10m upfront payment

  • AstraZeneca teams with Heptares

    AstraZeneca has teamed up with UK-based drug discovery company Heptares in a four-year collaboration to develop new therapies that target proteins linked to nervous system and cardiovascular disorders. ... The deal includes a £3.8m payment to Heptares,

More from news
Approximately 1 fully matching, plus 2 partially matching documents found.

Latest appointments

  • Former Amgen EVP Roger Perlmutter joins Heptares board Former Amgen EVP Roger Perlmutter joins Heptares board

    UK-based Heptares, which focuses on researching medicines that target G protein-coupled receptors across a range of conditions, has made several deals recently with large pharma companies, including AstraZeneca and ... We are delighted to welcome Roger

More from appointments
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
3 Monkeys Zeno

3 Monkeys Zeno is an award winning global creative communications consultancy – home to a collective of creative and strategic...

Latest intelligence

The UK’s new five-year pricing agreement
Pharma has agreed to capped growth again - in exchange for uptake promises...
Digital applications are transforming the market access landscape
Organisations are leveraging new technology to implement a wider range of business models and, in essence, drive market access success by working smarter, faster and with greater economy....
Escaping the spin cycle of sub-optimal launch
...

Infographics